Production (Stage)
Fennec Pharmaceuticals Inc.
FRX.TO
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -31.23% | 123.69% | 278.09% | 647.88% | 1,299.50% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -31.23% | 123.69% | 278.09% | 647.88% | 1,299.50% |
| Cost of Revenue | 75.44% | 152.90% | 384.85% | 560.79% | 846.96% |
| Gross Profit | -35.46% | 121.85% | 272.40% | 652.50% | 1,326.53% |
| SG&A Expenses | 6.90% | 26.82% | 50.57% | 39.17% | 46.32% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.81% | 32.18% | 58.14% | 41.02% | 40.64% |
| Operating Income | -291.97% | 120.11% | 109.85% | 124.48% | 125.67% |
| Income Before Tax | -594.83% | 99.56% | 94.40% | 110.34% | 110.91% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -607.67% | 97.28% | 94.40% | 110.34% | 110.91% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -607.67% | 97.28% | 94.40% | 110.34% | 110.91% |
| EBIT | -291.97% | 120.11% | 109.85% | 124.48% | 125.67% |
| EBITDA | -182.13% | -- | -- | -- | -- |
| EPS Basic | -634.35% | 98.26% | 94.97% | 110.12% | 109.99% |
| Normalized Basic EPS | -614.81% | 100.96% | 94.98% | 110.23% | 110.10% |
| EPS Diluted | -1,901.01% | 86.15% | 86.50% | 103.62% | 103.01% |
| Normalized Diluted EPS | -1,483.98% | 90.60% | 86.73% | 103.96% | 103.76% |
| Average Basic Shares Outstanding | 2.59% | 2.56% | 2.02% | 1.76% | 1.35% |
| Average Diluted Shares Outstanding | -1.19% | 6.41% | 5.86% | 5.62% | 5.23% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |